Physician

William B. Grow, M.D.

According to 2025 Medicare claims, William Grow, M.D. (NPI: 1407804578) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Orange, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32789-2988. Grow is affiliated with the MaineHealth Accountable Care Organization (ACO ID: A1290) and Mission Health Partners, LLC (ACO ID: A2591), participating under the MSSP model.

Grow's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 952 traditional Medicare patients, billed 232,012 HCPCS/CPT codes, and received $6,009,437 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,518 prescription claims across 375 beneficiaries totaling $4,575,880 in drug costs, led by Ibrance (Palbociclib). DME data shows 35 claims. Open Payments data shows 21 records totaling $455. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $3,571,916 to $6,009,437. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,793,477 to $4,575,880. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,706 to $1,453.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	860	322,623	$3,571,916
2016	987	337,052	$3,628,630
2017	1,065	246,582	$4,516,573
2018	1,229	292,188	$5,341,038
2019	1,225	376,053	$5,652,125
2020	1,189	338,327	$5,451,503
2021	1,066	291,993	$5,514,458
2022	1,003	314,442	$5,833,445
2023	941	241,199	$5,213,209
2024	952	232,012	$6,009,437

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	221	1,411	$1,793,477
2016	238	1,324	$2,303,346
2017	273	1,687	$1,907,274
2018	330	2,010	$3,362,758
2019	346	2,381	$3,990,686
2020	350	2,503	$3,725,177
2021	360	2,672	$5,411,493
2022	348	2,337	$4,361,593
2023	350	2,269	$3,866,502
2024	375	2,518	$4,575,880

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	363	$132,997
2016	13	341	$114,991
2017	13	315	$84,137
2018	28	372	$61,738
2019	34	364	$52,765
2020	26	432	$53,696
2021	42	490	$70,326
2022	27	207	$15,669
2023	N/R	131	$38,553
2024	N/R	35	$1,029

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	558	1,511	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	398	517	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	617	1,091	$13
36415	Insertion of needle into vein for collection of blood sample	833	2,698	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	824	2,705	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	52	1,442	$814,339
Brukinsa	Zanubrutinib	34	1,020	$451,037
Xtandi	Enzalutamide	33	990	$433,775
Welireg	Belzutifan	13	390	$387,535
Revlimid	Lenalidomide	17	476	$290,319

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$747
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	21	$455	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for William B. Grow, M.D.?

Tedicare shows public-source Medicare data for William B. Grow, M.D. (NPI 1407804578), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does William B. Grow, M.D. have ACO affiliation data?

William B. Grow, M.D. is shown with ACO affiliation data for MaineHealth Accountable Care Organization (MSSP, ACO ID A1290) and Mission Health Partners, LLC (MSSP, ACO ID A2591).

What billing organization is linked to William B. Grow, M.D.?

William B. Grow, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does William B. Grow, M.D. have Open Payments data?

William B. Grow, M.D. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.